GSK3B, glycogen synthase kinase 3 beta, 2932

N. diseases: 393; N. variants: 25
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.340 Biomarker group CTD_human Glycogen synthase kinase 3 regulates cell death and survival signaling in tumor cells under redox stress. 25246272 2014
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.340 Biomarker group BEFREE GSK-3 inhibitors reduce prostate tumor cell growth; however, it is not clear if both isoforms, GSK-3α and GSK-3β, are involved. 22539113 2012
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.340 AlteredExpression group LHGDN Expression of the fat-1 gene diminishes prostate cancer growth in vivo through enhancing apoptosis and inhibiting GSK-3 beta phosphorylation. 18852124 2008
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.340 Biomarker group CTD_human PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer. 16421604 2006
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.340 Biomarker group LHGDN Glycogen synthase kinase-3beta suppression eliminates tumor necrosis factor-related apoptosis-inducing ligand resistance in prostate cancer. 14617795 2003
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.340 PosttranslationalModification group LHGDN Alleviating the suppression of glycogen synthase kinase-3beta by Akt leads to the phosphorylation of cAMP-response element-binding protein and its transactivation in intact cell nuclei. 12900420 2003